GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Audentes Therapeutics Inc (NAS:BOLD) » Definitions » Price-to-Tangible-Book

Audentes Therapeutics (Audentes Therapeutics) Price-to-Tangible-Book : 7.38 (As of Apr. 26, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Audentes Therapeutics Price-to-Tangible-Book?

As of today (2024-04-26), Audentes Therapeutics's share price is $59.97. Audentes Therapeutics's Tangible Book per Share of Sep. 2019 for the quarter that ended in Sep. 2019 was $8.13. Hence, Audentes Therapeutics's Price to Tangible Book Ratio of today is 7.38.

The historical rank and industry rank for Audentes Therapeutics's Price-to-Tangible-Book or its related term are showing as below:

BOLD's Price-to-Tangible-Book is not ranked *
in the Biotechnology industry.
Industry Median: 2.68
* Ranked among companies with meaningful Price-to-Tangible-Book only.

A closely related ratio is called PB Ratio. As of today, Audentes Therapeutics's share price is $59.97. Audentes Therapeutics's Book Value per Sharefor the quarter that ended in Sep. 2019 was $8.38. Hence, Audentes Therapeutics's P/B Ratio of today is 7.15.


Audentes Therapeutics Price-to-Tangible-Book Historical Data

The historical data trend for Audentes Therapeutics's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Audentes Therapeutics Price-to-Tangible-Book Chart

Audentes Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Price-to-Tangible-Book
Get a 7-Day Free Trial - - 3.68 6.45 2.15

Audentes Therapeutics Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
Price-to-Tangible-Book Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.96 2.15 4.37 4.21 3.46

Competitive Comparison of Audentes Therapeutics's Price-to-Tangible-Book

For the Biotechnology subindustry, Audentes Therapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Audentes Therapeutics's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Audentes Therapeutics's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Audentes Therapeutics's Price-to-Tangible-Book falls into.



Audentes Therapeutics Price-to-Tangible-Book Calculation

Audentes Therapeutics's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: Sep. 2019 )
=59.97/8.129
=7.38

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.


Audentes Therapeutics Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Audentes Therapeutics's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.


Audentes Therapeutics (Audentes Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
600 California Street, 17th Floor, San Francisc, CA, USA, 94108
Audentes Therapeutics Inc is a biotechnology company. It is engaged in developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. Some of the development products of the company consist of AT132, AT342, AT982, and others.
Executives
Louis G Lange director 3172 PORTER DRIVE, PALO ALTO CA 94034
Natalie C. Holles officer: President and COO C/O HYPERION THERAPEUTICS, INC., 2000 SIERRA POINT PARKWAY, SUITE 400, BRISBANE CA 94005
Edward R. Conner officer: SVP, Chief Medical Officer 501 CANAL BLVD., POINT RICHMOND TECH CENTER, RICHMOND CA 94804
Thomas P Soloway officer: Executive Vice President, CFO C/O AUDENTES THERAPEUTICS, INC., 600 CALIFORNIA ST., 17TH FLOOR, SAN FRANCISCO CA 94108
Eric Mosbrooker officer: SVP, Chief Commercial Officer C/O HORIZON PHARMA, PLC, ADELAIDE CHAMBERS, PETER STREET, DUBLIN 8 L2 000000
Mark Alan Goldberg director 128 SPRING STREET, SUITE 520, LEXINGTON MA 02421
Matthew R Patterson director, officer: Chief Executive Officer C/O AMICUS THERAPEUTICS, INC., 6 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Julie Smith director C/O RAPTOR PHARMACEUTICAL CORP, 9 COMMERCIAL BLVD, SUITE 200, NOVATO CA 94949
Scott W Morrison director C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT SUITE 101, SOUTH SAN FRANCISCO CA 94080
Jennifer Jarrett director C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Suyash Prasad officer: Senior VP & Chief Med Officer C/O AUDENTES THERAPEUTICS, INC., 101 MONTGOMERY ST., SUITE 2650, SAN FRANCISCO CA 94104
Kush Parmar director C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Orbimed Advisors Llc 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Capital Gp Iv Llc 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Stephen P Squinto director C/O ALEXION PHARMACEUTICALS INC, 352 KNOTTER DRIVE, CHESHIRE CT 06410

Audentes Therapeutics (Audentes Therapeutics) Headlines

From GuruFocus